A detailed history of Alps Advisors Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 34,231 shares of YMAB stock, worth $381,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,231
Previous 34,224 0.02%
Holding current value
$381,333
Previous $413,000 8.72%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.95 - $15.39 $69 - $107
7 Added 0.02%
34,231 $449,000
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.25 $396,998 - $590,364
34,224 New
34,224 $413,000
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $330,794 - $879,762
-50,503 Closed
0 $0
Q4 2021

Feb 09, 2022

SELL
$15.51 - $29.31 $45,072 - $85,174
-2,906 Reduced 5.44%
50,503 $819,000
Q3 2021

Nov 15, 2021

SELL
$27.47 - $37.31 $109,248 - $148,381
-3,977 Reduced 6.93%
53,409 $1.52 Million
Q2 2021

Aug 11, 2021

BUY
$25.45 - $37.64 $1.46 Million - $2.16 Million
57,386 New
57,386 $1.94 Million
Q4 2020

Feb 03, 2021

SELL
$37.86 - $54.26 $1.93 Million - $2.77 Million
-51,029 Closed
0 $0
Q3 2020

Nov 04, 2020

SELL
$35.13 - $43.62 $112,767 - $140,020
-3,210 Reduced 5.92%
51,029 $1.96 Million
Q2 2020

Aug 05, 2020

BUY
$23.66 - $49.53 $1.28 Million - $2.69 Million
54,239 New
54,239 $2.34 Million
Q4 2019

Feb 07, 2020

SELL
$23.81 - $33.78 $1.62 Million - $2.3 Million
-68,175 Closed
0 $0
Q3 2019

Nov 04, 2019

SELL
$21.57 - $31.37 $73,338 - $106,658
-3,400 Reduced 4.75%
68,175 $1.78 Million
Q2 2019

Aug 07, 2019

BUY
$19.51 - $28.31 $1.4 Million - $2.03 Million
71,575 New
71,575 $1.64 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.